{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:17:37Z","timestamp":1793945857439,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021316","name":"AstraZeneca Pharmaceuticals LP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jchf.2024.02.018","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T18:48:30Z","timestamp":1713379710000},"page":"999-1011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeted Metabolomic Profiling of Dapagliflozin in Heart\u00a0Failure With Preserved Ejection Fraction"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-7623","authenticated-orcid":false,"given":"Senthil","family":"Selvaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shachi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"McGarrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia Coulter","family":"Kwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl L.","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ilkayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Muehlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Newgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalane W.","family":"Kitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svati H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2024.02.018_bib1","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2024.02.018_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2024.02.018_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial metabolomics of human heart failure with preserved ejection fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.02.018_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","article-title":"Nitrosative stress drives heart failure with preserved ejection fraction","volume":"568","author":"Schiattarella","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jchf.2024.02.018_bib5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.122.060402","article-title":"Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF","volume":"146","author":"Selvaraj","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.02.018_bib6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jamacardio.2017.1239","article-title":"Sildenafil treatment in heart failure with preserved ejection fraction: targeted metabolomic profiling in the RELAX trial","volume":"2","author":"Wang","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.02.018_bib7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jchf.2024.02.018_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2337\/db20-0921","article-title":"SGLT2 inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: a randomized double-blind, placebo-controlled crossover trial","volume":"70","author":"Lauritsen","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.jchf.2024.02.018_bib9","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","article-title":"Implications of altered ketone metabolism and therapeutic ketosis in heart failure","volume":"141","author":"Selvaraj","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.02.018_bib10","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.02.018_bib11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \"thrifty substrate\" hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2024.02.018_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/science.abc8861","article-title":"Comprehensive quantification of fuel use by the failing and nonfailing human heart","volume":"370","author":"Murashige","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jchf.2024.02.018_bib13","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.115.020226","article-title":"Catabolic defect of branched-chain amino acids promotes heart failure","volume":"133","author":"Sun","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.02.018_bib14","article-title":"Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure","volume":"5","author":"Hunter","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2024.02.018_bib15","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: the randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2024.02.018_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcmg.2020.07.022","article-title":"Body composition, natriuretic peptides, and adverse outcomes in heart failure with preserved and reduced ejection fraction","volume":"14","author":"Selvaraj","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jchf.2024.02.018_bib17","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2024.02.018_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","article-title":"Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction","volume":"8","author":"Scandalis","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2024.02.018_bib19","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1002\/edm2.381","article-title":"The DAPA-DIET study: metabolic response to dapagliflozin combined with dietary carbohydrate restriction in patients with type 2 diabetes mellitus and obesity\u2014a longitudinal cohort study","volume":"5","author":"Hanson","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jchf.2024.02.018_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124844","article-title":"Metabolomic fingerprint of heart failure with preserved ejection fraction","volume":"10","author":"Zordoky","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2024.02.018_bib21","doi-asserted-by":"crossref","first-page":"H768","DOI":"10.1152\/ajpheart.00820.2016","article-title":"Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond","volume":"313","author":"Ruiz","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jchf.2024.02.018_bib22","first-page":"458","article-title":"Nutritional status of outpatients with chronic stable heart failure based on serum amino acid concentration","volume":"72","author":"Tsuji","year":"2018","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jchf.2024.02.018_bib23","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ejhf.1304","article-title":"Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart\u00a0Failure (SICA-HF)","volume":"20","author":"Emami","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2024.02.018_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/2047487318797395","article-title":"Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study","volume":"26","author":"Zhang","year":"2019","journal-title":"Eur J Prev Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924001823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924001823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T20:42:32Z","timestamp":1717706552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924001823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2213177924001823"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.02.018","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Metabolomic Profiling of Dapagliflozin in Heart\u00a0Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}